Reductions in World Health Organization Risk Drinking Levels as a Primary Efficacy End Point for Alcohol Clinical Trials

作者
Katie Witkiewitz,Raymond F. Anton,Stephanie S. O’Malley,Deborah S. Hasin,Bernard L. Silverman,Arnie Aldridge,Karl Mann,Henry R. Kranzler,Henri‐Jean Aubin,Michaela Hoffman,Conrad J. Wong,Didier Meulien,Gary A. Zarkin
出处
期刊:JAMA Psychiatry [American Medical Association]
卷期号:82 (12): 1246-1246 被引量:2
标识
DOI:10.1001/jamapsychiatry.2025.2508
摘要

Importance Alcohol use disorder (AUD) is a highly prevalent and costly psychiatric disorder. Abstinence has been considered the optimal outcome of treatment for AUD. Yet, most individuals with AUD do not seek treatment because they do not have a goal of abstinence. The Food and Drug Administration (FDA) has recently qualified reductions in drinking, defined by at least a 2-level reduction in the World Health Organization risk drinking levels (WHO RDLs), as a primary end point for alcohol pharmacotherapy trials. The approval of drinking reductions as an end point for alcohol clinical trials aligns with an accumulating literature on drinking reductions in the alcohol field. This article provides a narrative review of 34 articles that have examined WHO RDLs as a surrogate marker of how people with AUD feel and function. Observations Results from epidemiological studies, community samples, and clinical trials indicate that drinking reductions are associated with improvements in how patients feel and function, including reduced risk of substance use disorder and medical and psychiatric diseases and reductions in alcohol-related consequences, craving, and health care costs. Drinking reductions are also associated with improvements in functioning and quality of life. Drinking reductions are also achieved by most clinical trial participants, and effect sizes for the WHO RDL reductions for active medications vs placebo are similar to or better than alternative end points. Conclusions and Relevance The FDA acceptance of reduction in WHO RDLs as a primary end point for alcohol clinical trials may increase opportunities for AUD medications development, encourage patients to seek treatments that target drinking reductions, and engage clinicians in prescribing medications shown to be effective in supporting drinking reductions. The WHO RDLs may be particularly useful for targeted drinking reductions in clinical practice. Qualification of the WHO RDL end point facilitates a paradigm shift toward a harm reduction approach in AUD treatment.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
2秒前
放青松完成签到,获得积分10
4秒前
4秒前
CodeCraft的应助被空集采纳,获得10
4秒前
5秒前
junyang发布了新的文献求助10
5秒前
苗条梨愁发布了新的文献求助50
5秒前
RONGGE完成签到 ,获得积分10
5秒前
6秒前
renn发布了新的文献求助10
6秒前
haorandu发布了新的文献求助10
7秒前
7秒前
7秒前
852的应助被闫玉坤采纳,获得10
8秒前
牧百川发布了新的文献求助10
8秒前
kuakuapizza完成签到 ,获得积分10
8秒前
molihuakai的应助被野性的苗条采纳,获得10
9秒前
yyychenn发布了新的文献求助10
9秒前
cruise发布了新的文献求助10
9秒前
情怀的应助被lsq108采纳,获得10
9秒前
乾隆发布了新的文献求助10
9秒前
10秒前
Akim的应助被even采纳,获得10
10秒前
fzh完成签到 ,获得积分10
10秒前
D515发布了新的文献求助10
10秒前
蓝草完成签到,获得积分10
11秒前
冷酷向日葵完成签到,获得积分10
11秒前
心心发布了新的文献求助10
12秒前
Nole的应助被Ming采纳,获得10
13秒前
junyang完成签到,获得积分10
13秒前
13秒前
14秒前
范德华气体完成签到 ,获得积分10
14秒前
李健的粉丝团团长的应助被66采纳,获得10
15秒前
李建勋发布了新的文献求助10
15秒前
花木森林jl091121完成签到,获得积分10
15秒前
16秒前
16秒前
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183894
求助须知:如何正确求助?哪些是违规求助? 9573067
关于积分的说明 21829226
捐赠科研通 7780983
什么是DOI,文献DOI怎么找? 3434150
关于科研通互助平台的介绍 2558315
邀请新用户注册赠送积分活动 2480648